COVID-19: NAD+ deficiency may predispose the aged, obese and type 2 diabetics to mortality through its effect on SIRT1 activity
R. Miller, A.R. Wentzel, G.A. Richards
Published: 24 June 2020 - Medical Hypotheses Volume 144 (2020) 110044.
This article, published by Elsevier, says:
- “The SARS-CoV-2 hyperinflammatory response is associated with high mortality. This hypothesis suggests that a deficiency of nicotinamide adenine dinucleotide (NAD+) may be the primary factor related to the SARS-Cov-2 disease spectrum and the risk for mortality” (bold added)
- nal support with NAD+ and SIRT1 activators could minimise disease severity if administered prophylactically and or therapeutically. The significance of this hypothesis, if proven, has far-reaching consequences in the management of COVID-19 especially in third world countries, where resources and finances are limited." (bold added)
- “We hypothesize that reduced Nicotinamide Adenine Dinucleotide (NAD+) levels with consequent deficient activity of the NAD+ dependent molecule SIRT1, which modulates cytokine production, may be the factor that predisposes the aged, obese, type 2 diabetics and other vulnerable groups to an increased mortality." (bold added)